Process Development:

•Development and validation of analytical methods to ensure accurate quantification, purity assessment, and impurity profiling. 

•Characterization of raw materials, intermediates, and final APIs using techniques such as HPLC, GC, MS, NMR, and XRPD. 

•Stability studies and fo...

•Flexible and Scalable Manufacturing – Multi-purpose facilities with 50L to 5000L vessels, supporting kilo to MT batch sizes across all API development phases, from preclinical, clinical to commercial launch. 

•Commitment to Quality, Compliance, and Safety – RSM-compliant, ISO9001 certifi...

•Small-scale synthesis of reference compounds, chemical intermediates, and active pharmaceutical ingredients (APIs). 

•Rapid synthesis of hit and lead compounds for drug discovery and proof of concept (PoC) studies. 


•Multi-step complex synthesis of novel molecules includi...

•Reliable Raw Material Sourcing – Established primary and backup suppliers, leveraging 20 years of expertise and a database of 30,000+ molecules and 5,000+ global suppliers. 
•Rapid Supplier Assessment & Qualification – Comprehensive factory audits, QA/QC evaluations, and independent anal...

This whitepaper, AcceleDev: Advancing Innovation and Efficiency in Unnatural Amino Acid (UAA) Synthesis, explores the growing impact of UAAs in next-generation pharmaceuticals, highlighting their role in improving drug performance, stability, and targeted delivery. It outlines the expanding global market, projected to surpass $12 billion by 2032, while addressing key challenges—cost, scalability, and regulatory barriers—that hinder commercialization. AcceleDev’s proven expertise in cost-effective and scalable UAA synthesis is showcased through detailed case studies, demonstrating successful outcomes in green chemistry, high-yield processes, and complex molecule production. With over 10,000 completed synthesis projects and robust regulatory readiness, AcceleDev positions itself as a critical partner for biotech and pharma companies aiming to bring innovative UAA-based therapies to market.